Controlled release gastroresistant pharmaceutical formulations for oral administration containing bile acids and their salts
Patent 5300300 Issued on April 5, 1994. Estimated Expiration Date: 
April 1, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 1, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesGastric juice resistant gelatin capsules and a process for the production thereof Pharmaceutical composition of prolonged action containing bile acids Pharmaceutical formulations of acid labile substances for oral use Patent #: 4853230 InventorsApplicationNo. 861462 filed on 04/01/1992US Classes:424/456, Gelatin424/464, Tablets, lozenges, or pills424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)424/490Coated (e.g., microcapsules)ExaminersPrimary: Page, Thurman K.Assistant: Benston, William E. Jr. Attorney, Agent or FirmInternational ClassA61K 009/64Foreign Application Priority Data1991-04-12 ITAbstractControlled release pharmaceutical formulations for oral administration coated by an enterosoluble gastroresistant film, preferably selected from gastroresistant granulates, gastroresistant tablets, gastroresistant hard gelatine capsules containing powders or granulates or two or more tablets or oily suspensions, gastroresistant soft gelatine capsules containing oily suspensions and hard gelatine capsules containing gastroresistant granulates or two or more gastroresistant tablets, containing therapeutically effective amounts of a mixture of bile acids and their salts with alkali metals or organic bases, process for their preparation and therapeutic use thereof in the treatment of biliary calculoses, biliary dyspepsias, biliary cirrhosis and chronic and cholestatic hepatopathies. | |
